[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

855-907-3286

Email address

Clinical.Trials@bms.com

Condition

Ulcerative Colitis

Treatment type

Interventional

Investigational product

Ozanimod

Phase

Phase 3

Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT05644665

Study number

IM047010

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to evaluate the efficacy and safety of ozanimod compared with placebo in participants with ulcerative colitis (UC) in mainland China and Taiwan. The main study is composed of an induction period, maintenance period, safety follow-up, and participants meeting certain criteria will be given the opportunity to participate in an optional open label extension.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

Main Study:

  1. Eligible participants must be Chinese.
  2. Participant has had moderately to severely active UC diagnosed at least 3 months prior to first investigational product administration. Open-label Extension Period:
  3. Participants who have completed the Week 10 Visit and are non-responders at Week 10.
  4. Participants who have completed the Induction Period and entered the Maintenance Period experienced disease relapse during the Maintenance Period, or who have completed the Maintenance Period at Week 52.
Exclusion criteria

Main Study and Open

  1. Participant has severe extensive colitis, diagnosis of CD, indeterminate colitis, presence or history of a fistula consistent with CD, microscopic colitis, radiation colitis, or ischemic colitis. Open-label Extension Period:
  2. Participant has clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the participant at risk by continuing the study or that would have required a participant to discontinue treatment were observed during the Induction Period or Maintenance Period.
  3. Participant has clinically relevant cardiovascular conditions, including history or presence of recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, Class III/IV heart failure, sick sinus syndrome, or severe untreated sleep apnea were observed during the Induction Period or Maintenance Period.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site